Year-end index target at 15,000. Taiwan equity market’s performance in 2020 largely tracked consensus earnings growth expectation of around 15%. We believe performance in 2021 will be partly supported by a similar earnings growth pace of 14%, though index upside could be capped if we see some rotation out of tech, which accounted for 70% of the index. Meanwhile, valuation should sustain above cycle average, bolstered by low rates, liquidity and above cycle ROE. Therefore, we set year-end 2021 index target at 15,000.
Lesser drag in 2020, smaller rebound in 2021. Taiwan is one of the very few markets in Asia expected to see positive GDP and EPS growth in 2020, though this has also set up Taiwan for a smaller post-COVID-19 rebound. However, the market is expected to see another 14% profit growth in 2021, driven by global growth, with sales growth accelerating to 5% from 3%, which is consistent with improving Taiwan GDP growth to 4% from 2.5%. Meanwhile, we expect earnings revisions to stay slightly positive on global PMI support and tech demand strength sustaining into early-2021. On policy, 2021 will likely be a muted year, though Taiwan should still benefit from the residual effect of on-shoring investment and capital repatriation. Hence, with a weak USD outlook, TWD may see some appreciation.
Broad-based recovery and shift within tech growth. While we expect Taiwan to see a similar earnings growth pace in 2021 as in 2020, the growth mix will likely differ considerably. A cyclical earnings rebound in 2021 with moderating but still resilient tech profit growth should result in an apparent broadening of earnings growth for the market. Also within tech, we expect a shift in earnings growth from semi (partly off a high 2020 base) to other parts of tech, as demand strength shifts from WFH to other core themes (5G, cloud and data-centre). Importantly, we believe, given QFII’s extreme overweight in upstream tech (2.6 SD above the long-term trend) it may leave plenty of room for rotation in 2021 as EPS growth broadens notably to other sectors in the market.
Stock calls. Our top picks for 2021 are Mediatek, TSMC, Largan, Quanta, and Accton within tech. In non-tech, we like Yuanta, Nien Made, Merida, and CTBC Holding. Our least preferred names are Makalot, First FHC, Asustek, and CHT.
相关报告
《投资至简》:一看就懂的价值投资策略
1.4w+
类型:读书笔记
上传时间:2021-03
标签:投资、价值投资、投资策略)
语言:中文
金额:8.8元
《财富是认知的变现》读书笔记-绛紫
5882
类型:读书笔记
上传时间:2022-04
标签:思维认知、投资策略、财富复利)
语言:中文
金额:9.9元
高盛2万字报告:2024年新兴市场展望(中英对照)
4261
类型:宏观
上传时间:2023-12
标签:新兴市场、投资策略、货币政策)
语言:中英
金额:7元
策略研究框架:少即是多-20210713-海通证券-72页
3952
类型:策略
上传时间:2021-07
标签:投资策略、研究框架)
语言:中文
金额:5积分
高盛1.4万字报告-2024年资产管理展望:拥抱新现实(中英对照)
3913
类型:行研
上传时间:2023-11
标签:投资策略、市场前景、政经风险)
语言:中英
金额:5元
-2022年中国政府工作报告宏观、投资策略及行业分析
3569
类型:宏观
上传时间:2022-03
标签:政府、投资策略、宏观)
语言:中文
金额:5积分
新能源汽车产业链2021年度投资策略-20201203-五矿证券-67页
2697
类型:行研
上传时间:2020-12
标签:新能源汽车、2021、投资策略)
语言:中文
金额:5积分
J.P. 摩根-全球投资策略-ESG投资2021:更快、更深、更广-2021.5.13-147页
2571
类型:策略
上传时间:2021-05
标签:投资策略、ESG)
语言:英文
金额:5积分
医美行业2021年中期投资策略报告-20210701-万联证券-50页
1852
类型:行研
上传时间:2021-07
标签:医美、2021中期、投资策略)
语言:中文
金额:5积分
2021年医药生物行业年度投资策略:全面国际化,迎接“十四五”-20201125-国信证券-129页
1753
类型:行研
上传时间:2020-11
标签:医药生物、十四五、投资策略)
语言:中文
金额:免费
积分充值
30积分
6.00元
90积分
18.00元
150+8积分
30.00元
340+20积分
68.00元
640+50积分
128.00元
990+70积分
198.00元
1640+140积分
328.00元
微信支付
余额支付
积分充值
应付金额:
0 元
请登录,再发表你的看法
登录/注册